WR99210
WR99210 structure
|
Common Name | WR99210 | ||
|---|---|---|---|---|
| CAS Number | 47326-86-3 | Molecular Weight | 394.68400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H18Cl3N5O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of WR99210WR99210 is a effective inhibitor of dihydrofolate reductase (DHFR) with an IC50 of <0.075 nM[1]. WR99210 is effective against the most pyrimethamine-resistant Plasmodium falciparum strains[2]. |
| Name | 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | WR99210 is a effective inhibitor of dihydrofolate reductase (DHFR) with an IC50 of <0.075 nM[1]. WR99210 is effective against the most pyrimethamine-resistant Plasmodium falciparum strains[2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: <0.075 nM (DHFR)[1] |
| References |
| Molecular Formula | C14H18Cl3N5O2 |
|---|---|
| Molecular Weight | 394.68400 |
| Exact Mass | 393.05300 |
| PSA | 98.46000 |
| LogP | 3.23810 |
| RIDADR | NONH for all modes of transport |
|---|
|
Development of a genetic tool for functional screening of anti-malarial bioactive extracts in metagenomic libraries.
Malaria Journal 14 , 233, (2015) The chemical treatment of Plasmodium falciparum for human infections is losing efficacy each year due to the rise of resistance. One possible strategy to find novel anti-malarial drugs is to access th... |
|
|
Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum.
PLoS ONE 7(7) , e40416, (2012) Mechanisms of drug resistance in Plasmodium vivax have been difficult to study partially because of the difficulties in culturing the parasite in vitro. This hampers monitoring drug resistance and res... |
|
|
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Antimicrob. Agents Chemother. 46(11) , 3362-9, (2002) The ongoing selection of multidrug-resistant strains of Mycobacterium tuberculosis has markedly reduced the effectiveness of the standard treatment regimens. Thus, there is an urgent need for new drug... |
| 1,6-Dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine |